Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.34
-0.04 (-0.02%)
AAPL  259.26
-0.11 (-0.04%)
AMD  207.45
+4.28 (2.11%)
BAC  55.09
-0.76 (-1.36%)
GOOG  328.16
-0.98 (-0.30%)
META  646.34
-6.72 (-1.03%)
MSFT  478.77
-0.51 (-0.11%)
NVDA  184.09
-0.78 (-0.42%)
ORCL  200.00
+1.48 (0.75%)
TSLA  448.81
+3.80 (0.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.